Specialst Programme : Aldo-keto reductases (AKRs), BaP Therapgy and drug redeployment strategies for accelerating thraphy development for haematological cancers

Khanim, Farhat (Co-Investigator)
Drayson, Mark (Principal Investigator)

Biosciences

Short title	Specialst Programme : Aldo-keto reductases (AKRs), BaP Therapgy and drug redeployment strategies for accelerating thraphy development for haematological cancers
Status	Finished
Effective start/end date	1/10/13 → 31/12/19

Funding

BLOODWISE

1 Article

Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
Jiang, Y., Southam, A. D., Trova, S., Beke, F., Alhazmi, B., Francis, T., Radotra, A., Di Maio, A., Drayson, M. T., Bunce, C. M. & Khanim, F. L., 22 Oct 2021, In: British Journal of Cancer. 126, 2, p. 275-286 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
60 Downloads (Pure)